Drug facts

Semaglutide and obstructive sleep apnea

By David Chen·Editor·Reviewed September 2026

Is semaglutide approved for it?¹²

No. The phrase “sleep apnea” does not appear anywhere in Wegovy’s label: not in the approved uses, not in the trial results, not in the warnings. Ozempic’s label does not mention it either. To approve a drug for sleep apnea, the FDA reviews trials that measured the sleep apnea itself. Semaglutide has no such approval.

Which GLP-1 drug is approved⁵⁶

Tirzepatide, sold for weight loss as Zepbound, is approved to treat moderate to severe obstructive sleep apnea in adults with obesity. The approval rests on the SURMOUNT-OSA trials, which enrolled adults with an average of about 50 breathing interruptions an hour. After 52 weeks, tirzepatide cut about 20 to 24 more events an hour than placebo, measured by the apnea-hypopnea index (AHI). It is a different molecule from semaglutide, so its results do not transfer automatically. See how the two compare.

What semaglutide studies show⁸⁷

The strongest semaglutide-specific data are observational. A 2026 study of health records from a large research network compared about 191,000 adults with obesity on semaglutide with a matched group not on it. Those on semaglutide were about 38% less likely to be diagnosed with sleep apnea later. Among roughly 40,000 people who already had both obesity and sleep apnea, semaglutide users had fewer deaths, heart events and kidney events over follow-up.

Record studies like this can show an association, not a cause. People prescribed semaglutide may differ from those who are not in ways that matching cannot fully capture, and a diagnosis code is not a sleep test. A 2026 review of the field sums it up: semaglutide offers important indirect evidence through weight and heart outcomes, but direct sleep-apnea outcome data remain limited. The randomized sleep-apnea evidence so far comes mainly from liraglutide and tirzepatide.

Why weight loss can help⁷⁴

In obesity-related sleep apnea, extra fat around the tongue, throat, chest and abdomen makes the airway more likely to narrow or collapse during sleep. The review above calls weight-loss-driven unloading of the airway the most likely explanation for how these drugs help, while noting it has not yet been confirmed with repeated airway imaging in treated patients. Semaglutide produces substantial weight loss: in Wegovy’s largest trial, adults lost 14.9% of their body weight over 68 weeks on 2.4 mg, against 2.4% on placebo. Whether that is enough to change a given person’s sleep apnea can only be told by testing.

If you use CPAP⁷

Keep using it. The review’s authors say incretin drugs should be seen as part of a combined plan, not an automatic replacement for positive airway pressure, and that PAP should not be stopped without repeat objective sleep testing. If you lose a lot of weight, your settings may need to change, which is a reason to tell your sleep clinician you started semaglutide, compounded or not.

What semaglutide is approved for³

• Cardiovascular risk reduction: lowering the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke in adults with established cardiovascular disease and either obesity or overweight.
• Weight reduction and long-term maintenance, in adults and in patients aged 12 and older with obesity, or adults with overweight and a weight-related condition.
• Noncirrhotic MASH with moderate to advanced liver fibrosis, under accelerated approval, which means continued approval may depend on a confirmatory trial.

Compounded semaglutide carries none of these approvals on its own and has not been tested for sleep apnea. Follow your pharmacy label and prescriber on dosing.